Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

OBJECTIVE: Natalizumab is a humanized recombinant monoclonal antibody against very late activation antigen-4 approved for the treatment of patients with multiple sclerosis (MS). A phase II study failed to demonstrate a difference between natalizumab treatment groups and the placebo group with regard...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Stüve, O, Cravens, P D., Frohman, E M., Phillips, J T., Remington, G M., von Geldern, G, Cepok, S, Singh, M P., Cohen Tervaert, J W., De Baets, M, MacManus, D, Miller, D H., Radü, E W., Cameron, E M., Monson, N L., Zhang, S, Kim, R, Hemmer, B, Racke, M K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Academy of Neurology 2009
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2677530/
https://ncbi.nlm.nih.gov/pubmed/18987352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/01.wnl.0000327341.89587.76
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak